View Older Stories View More Recent Stories
-
Solventum (SOLV) PT Lowered to $92 at KeyBanc
-
Q1 MedTech quarterly preview: BTIG
-
Solventum (SOLV) PT Lowered to $92 at Piper Sandler
-
BTIG Reiterates Buy Rating on Solventum (SOLV)
-
Rothschild Redburn Starts Solventum (SOLV) at Sell
-
CIBC Reiterates on Solventum (SOLV): 'guidance had some conservatism,' potential upside
-
Jefferies on Solventum (SOLV): we still see margin upside to estimates
-
Piper Sandler's Top Medical Technology Picks Exiting 4Q-25 EPS Season
-
Piper Sandler: 'Solventum (SOLV) Continues to be Top Idea'
-
Solventum Corporation (SOLV) Misses Q4 EPS by 18c ; Offers Guidance
-
KeyBanc on Medical Technology: 'From Reset to Rebound?'
-
KeyBanc Upgrades Solventum (SOLV) to Overweight
-
Mizuho Upgrades Solventum (SOLV) to Outperform
-
Solventum (SOLV) PT Raised to $105 at Stifel: A Multi-Year Turnaround Story in Store
-
Piper Sandler: Solventum (SOLV) a Top Idea for 2026
-
Solventum receives top healthcare supply chain certification from HIRC
-
BTIG Upgrades Solventum (SOLV) to Buy
-
UBS Reiterates Neutral Rating on Solventum (SOLV) On Acera Deal & Buy Back Announcement
-
Solventum Corporation (SOLV) Misses Q3 EPS by 27c ; Offers Guidance
-
UBS Starts Solventum (SOLV) at Neutral
-
Jefferies Starts Solventum (SOLV) at Hold
-
Solventum prices $2 billion debt tender offer with premium rates
-
Solventum launches $1.75 billion debt tender offers
-
Solventum Corporation (SOLV) Files for 34.37M Share Offering by 3M Company
-
Solventum (SOLV) PT Raised to $94 at Piper Sandler
-
Solventum Corporation (SOLV) Tops Q2 EPS by 1c ; Offers Guidance
-
Solventum Corporation (SOLV) 2200 contracts of September 75 calls trade
-
Morgan Stanley Upgrades Solventum (SOLV) to Overweight
-
KeyBanc Starts Solventum (SOLV) at Sector Weight
-
Piper Sandler Highlights 'Best Value Stocks' in Medical Technology
-
Piper Sandler Upgrades Solventum (SOLV) to Overweight
-
Solventum Corporation (SOLV) Misses Q1 EPS by 23c ; Offers Guidance
-
Solventum (SOLV) partners with SprintRay
-
Stifel Reiterates Buy Rating on Solventum (SOLV)
-
Solventum (SOLV) PT Raised to $85 at Mizuho
-
Solventum Corporation (SOLV) to Present Value Creation Formula and Long-Range Plan at 2025 Investor Day
-
Solventum (SOLV) PT Raised to $84 at Piper Sandler
-
Solventum Corporation (SOLV) Misses Q4 EPS by 9c ; Offers Guidance
-
Trian says Solventum (SOLV) will deliver faster organic growth and higher margins as standalone company
-
Trian Fund Management to Push Solventum Corporation (SOLV) to Separate More Business Units - WSJ
-
Thermo Fisher Scientific (TMO) to Acquire Solventum’s (SOLV) Purification and Filtration Business for $4.1B Cash
-
Trian Issues Open Letter to Solventum (SOLV) Shareholders
-
Trian's Nelson Peltz Sends Letter to Solventum (SOLV) Holders - CNBC
-
Mizuho Starts Solventum (SOLV) at Neutral
-
Solventum Corporation (SOLV) Launches First 3D Printed Aligner Attachments
-
Solventum (SOLV) PT Raised to $75 at Piper Sandler
-
Solventum Corporation (SOLV) Tops Q3 EPS by 10c; offers guidance
-
Solventum Corporation (SOLV) to Explore Sale of Purification and Filtration Unit - WSJ
-
Solventum Corporation (SOLV) Appoints Ryan Egeland as Chief Medical Officer
-
Stifel Starts Solventum (SOLV) at Buy

